Tune Therapeutics
Hilary Walton has been working in the field of laboratory operations since 2010. Hilary began their career as a Research Technician II at Washington University School of Medicine in 2010. In 2013, they became a Graduate Research Assistant at Duke University. Hilary then moved to Resilient Biotics in 2018, where they worked as a Scientist and Laboratory Operations Manager. In 2022, they began their current role as a Laboratory Operations Manager at Tune Therapeutics.
Hilary Walton completed their Bachelor of Science (BS) in Microbiology, General from Indiana University Bloomington in 2010. Hilary then obtained Select Agent certification from the CDC in February 2010. Hilary went on to pursue their Doctor of Philosophy (PhD) in Molecular Genetics and Microbiology from Duke University, which they completed in 2018.
Tune Therapeutics
1 followers
With its versatile and powerful TEMPO epigenomic control platform, Tune Therapeutics is pioneering a new therapeutic modality that can fine-tune any gene network and unlock the full power and potential of regenerative medicine. With deep experience and a passionate commitment to exploration and innovation, Tune is driving through an inflection point in the history of genetic medicine: from targeting a limited range of rare conditions, to addressing thousands of common and complex diseases for which no curative treatment is available.